Literature DB >> 18512245

Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease.

Lisa M Lix1, Lesley A Graff, John R Walker, Ian Clara, Patricia Rawsthorne, Linda Rogala, Norine Miller, Jason Ediger, Thea Pretorius, Charles N Bernstein.   

Abstract

BACKGROUND: The aim was to assess quality of life (QOL) and psychological functioning in inflammatory bowel disease (IBD) as related to patterns of disease activity over time.
METHODS: Study participants were 388 recently diagnosed individuals from the population-based Manitoba IBD Cohort Study. They completed mail-out surveys at 6-month intervals and clinical interviews annually. Based on their 2-year pattern of self-reported disease activity, participants were assigned to 1 of 3 groups: consistently active, fluctuating, or consistently inactive disease. Disease type (Crohn's disease [CD] or ulcerative colitis [UC]) was confirmed through chart review. Change over time was modeled for measures of QOL and positive and negative psychological functioning using mixed-effects regression analyses.
RESULTS: Half of the participants had fluctuating disease activity, while almost one-third of participants reported consistent active disease. Participants with the fluctuating activity pattern showed significant improvement in disease-specific QOL compared to participants with consistent activity. Perceived stress, health anxiety, and pain anxiety decreased while pain catastrophizing and mastery increased over time, although the amount of change was not significantly different among disease activity patterns. However, when the data were averaged over time there were significant differences among disease activity patterns on most outcomes. Significant effects of CD versus UC were observed only for the pain measures.
CONCLUSIONS: Change in IBD QOL is influenced by one's longitudinal profile of disease activity, but change in psychological functioning is not. Effects of disease activity on psychological functioning were modest, suggesting that disease has an impact even when patients are not experiencing active symptoms.

Entities:  

Mesh:

Year:  2008        PMID: 18512245     DOI: 10.1002/ibd.20511

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  67 in total

1.  Analysis of function and predictors of failure in women undergoing repair of Crohn's related rectovaginal fistula.

Authors:  Galal El-Gazzaz; Tracy Hull; Emilio Mignanelli; Jeffery Hammel; Brook Gurland; Massarat Zutshi
Journal:  J Gastrointest Surg       Date:  2010-03-16       Impact factor: 3.452

2.  Outcomes and Factors Associated With Reduced Symptoms in Patients With Gastroparesis.

Authors:  Pankaj J Pasricha; Katherine P Yates; Linda Nguyen; John Clarke; Thomas L Abell; Gianrico Farrugia; William L Hasler; Kenneth L Koch; William J Snape; Richard W McCallum; Irene Sarosiek; James Tonascia; Laura A Miriel; Linda Lee; Frank Hamilton; Henry P Parkman
Journal:  Gastroenterology       Date:  2015-08-21       Impact factor: 22.682

3.  Functional dyspepsia.

Authors:  Rita Brun; Braden Kuo
Journal:  Therap Adv Gastroenterol       Date:  2010-05       Impact factor: 4.409

Review 4.  Pain and inflammatory bowel disease.

Authors:  Klaus Bielefeldt; Brian Davis; David G Binion
Journal:  Inflamm Bowel Dis       Date:  2009-05       Impact factor: 5.325

5.  Measures of relative importance for health-related quality of life.

Authors:  Tolulope T Sajobi; Lisa M Lix; Ian Clara; John Walker; Lesley A Graff; Patricia Rawsthorne; Norine Miller; Linda Rogala; Rachel Carr; Charles N Bernstein
Journal:  Qual Life Res       Date:  2011-04-24       Impact factor: 4.147

6.  Optimizing management of Crohn's disease within a project management framework: results of a pilot study.

Authors:  Laurie Keefer; Bethany Doerfler; Caroline Artz
Journal:  Inflamm Bowel Dis       Date:  2011-02-23       Impact factor: 5.325

7.  Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.

Authors:  Remo Panaccione; Edward V Loftus; David Binion; Kevin McHugh; Shamsul Alam; Naijun Chen; Benoît Guerette; Parvez Mulani; Jingdong Chao
Journal:  Can J Gastroenterol       Date:  2011-08       Impact factor: 3.522

8.  Neonatal immune challenge followed by adult immune challenge induces epigenetic-susceptibility to aggravated visceral hypersensitivity.

Authors:  J E Aguirre; J H Winston; S K Sarna
Journal:  Neurogastroenterol Motil       Date:  2017-04-25       Impact factor: 3.598

9.  Mechanisms of Quality of Life and Social Support in Inflammatory Bowel Disease.

Authors:  Laura Katz; Dean A Tripp; Mark Ropeleski; William Depew; J Curtis Nickel; Stephen Vanner; Michael J Beyak
Journal:  J Clin Psychol Med Settings       Date:  2016-03

10.  Long-term follow-up with Granulocyte and Monocyte Apheresis re-treatment in patients with chronically active inflammatory bowel disease.

Authors:  Annelie Lindberg; Michael Eberhardson; Mats Karlsson; Per Karlén
Journal:  BMC Gastroenterol       Date:  2010-07-06       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.